Genta Completes Initial Clinical Dosing of G4544

Genta released findings from the initial dosing of a Phase I study of G4544, a treatment for diseases associated with accelerated bone loss.

The trial evaluated escalating single doses of G4544 in 30 normal volunteers. The endpoints of the study were to determine safety and assess pharmacokinetics and oral bioavailability.

The drug was tested over a dosing range of 30–150 mg, and no adverse effects attributable to G4544 were observed. Complete pharmacokinetic assessment of higher dose levels is pending further analyses, Genta said.